MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Thyreogen Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Thyreogen (Thyroid Cytomax A-2) is a Khavinson thyroid peptide bioregulator: a complex of short peptide fractions (up to about 5000 Da) extracted from calf thyroid tissue. Rather than acting as a hormone, it is hypothesized to deliver regulatory peptides that enter thyroid cells, bind DNA promoter regions, and modulate genes controlling thyrocyte metabolism, self-renewal, and the synthesis of T3, T4, and calcitonin (PMID 34834147). It is sold as an oral capsule containing 10 mg of peptide complex A-2; the usual regimen is 1-2 capsules once or twice daily before meals for a one-month course, repeated two to three times a year. Injectable thyroid cytomedin counterparts such as Thyramin have been studied in age-related hypothyroidism and autoimmune thyroiditis with reported normalization of thyroid indices and lower autoantibody titres, but no large randomized trials exist (PMID 16075681). Thyreogen is not FDA or EMA approved. The educational subcutaneous reference uses a 20 mg vial reconstituted with 2 mL of water (10 mg/mL), so 1-2 mg is 10-20 units. Reference information, not medical advice.
Reconstitute: Add 2 mL bacteriostatic water → 10 mg/mL concentration.
Typical dose: 1-2 mg/day SC (educational); 10 mg/capsule oral
Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 0.1 mg (100 mcg) on a U-100 insulin syringe.
Storage: Capsules: store in a cool, dry place at about 15-25 °C, away from light and moisture. For the educational lyophilized-vial model: store at -20 °C long term, or 2-8 °C for short periods, protected from light; once reconstituted, keep refrigerated at 2-8 °C and use within about 3-4 weeks.
Half-life: Not formally characterized; the intact peptide fractions are likely hydrolyzed within minutes by peptidases, with effects attributed to downstream gene-expression changes that outlast the peptides themselves.
Route: Real-world product is an oral capsule (10 mg peptide complex A-2 per capsule; a sublingual 'lingual' form also exists); this page models a once-daily subcutaneous reconstitution reference, a route not clinically validated for Thyreogen.
Status: Not FDA or EMA approved; registered in Russia as a dietary peptide supplement and sold for research or educational use elsewhere; no large randomized trials. Distinct from Thyrogen (thyrotropin alfa).
About Thyreogen
Thyreogen is a thyroid-targeted Khavinson peptide bioregulator, a "cytomax" complex of short peptide fractions extracted from calf thyroid tissue and studied for its proposed ability to normalize gene expression and metabolism in thyroid cells [1][2]. In the original Russian gerontology framework these preparations are taken as oral capsules (the Cytomax line) or, in their pharmaceutical cytomedin form, given by intramuscular injection; clinically Thyreogen itself is an oral capsule containing 10 mg of peptide complex A-2, so the subcutaneous figures below are an educational reconstitution reference modeled on the injectable bioregulator convention, not the validated oral regimen. No large randomized human trials of Thyreogen exist, so every dose here is illustrative only [3].\n\nThe real-world Thyreogen dosage is 1-2 capsules taken one to two times daily, 15-20 minutes before meals (about 10-40 mg of peptide complex per day), in one-month courses repeated two to three times per year.\n\nEducational guide for reconstitution and short-course dosing.\n\nFrequency: Inject once daily subcutaneously during a short course of roughly 10-20 days, with courses typically repeated two to three times per year in the bioregulator literature [1]. Reconstituting a 20 mg vial with 2 mL of bacteriostatic water yields 10 mg/mL, so a 1-2 mg daily dose corresponds to 10-20 units on a U-100 insulin syringe. The actual marketed product is an oral capsule taken before meals, and no injection is involved in normal use.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2 mL of bacteriostatic water into a sterile syringe (note: the real Thyreogen product is an oral capsule and requires no reconstitution; this is an educational injectable model only).
Inject the water slowly down the inner wall of the 20 mg vial; do not spray it directly onto the lyophilized powder.
Gently swirl or roll the vial until the powder fully dissolves into a clear solution; never shake, which can shear the peptides and cause foaming.
The result is 10 mg/mL, so 1 mg is 10 units (0.1 mL) and 2 mg is 20 units (0.2 mL) on a U-100 insulin syringe; swab the stopper and draw your daily dose.
Inject subcutaneously once daily during the course, store the vial refrigerated at 2-8 °C between uses, and discard after the stability window (about 3-4 weeks).
Interactive Thyreogen Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 2mL water yields 10.00 mg/mL. To evaluate a 250mcg dose, pull to 2.5 units (3 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Microdose intro (days 1-3) | 500 mcg | 5 units (0.05 mL) |
| Conservative course (days 1-10) | 1000 mcg (1 mg) | 10 units (0.10 mL) |
| Standard course (days 1-10) | 2000 mcg (2 mg) | 20 units (0.20 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Thyreogen, 20 mg each):
- checkOne 10-day course at the standard 2 mg/day uses a full 20 mg vial (a 1 mg/day course uses about half a vial).
- check8-week window (about 2 short courses): 2 vials.
- check12-week window (about 3 short courses): 3 vials.
- check16-week window (about 4 short courses): 4 vials.
Insulin Syringes (U-100):
- checkOne 0.3 mL (30-unit) syringe per daily injection, about 10 per 10-day course.
- check8-week window: roughly 20 syringes.
- check12-week window: roughly 30 syringes.
- check16-week window: roughly 40 syringes.
Bacteriostatic Water (30 mL bottles): Use 2 mL per vial for reconstitution.
- checkEach reconstituted 20 mg vial consumes 2 mL of bacteriostatic water.
- checkEven 4 vials across a 16-week schedule use only about 8 mL, so a single 30 mL bottle covers every course.
- checkDiscard any vial not used within its stability window rather than over-diluting to extend it.
Alcohol Swabs: clean the vial stopper and injection site before each use.
- checkUse 2 swabs per injection (vial top plus skin), about 20 per 10-day course.
- check8-week window: about 40 swabs; 12-week window: about 60 swabs; 16-week window: about 80 swabs.
- checkA single 100-count box comfortably covers a full year of seasonal courses.
Mechanism of Action (MOA)
Thyreogen is the trade name for a thyroid "cytomax," a complex of low-molecular-weight peptide fractions (up to roughly 5000 Da) extracted from the thyroid glands of young calves under Vladimir Khavinson's bioregulation program at the St. Petersburg Institute of Bioregulation and Gerontology [1][6]. It sits within a family of tissue-derived peptide preparations originally called cytomedins: the injectable pharmaceutical form of the thyroid cytomedin is marketed as Thyramin, while Thyreogen is the oral capsule (cytomax) version. These products are positioned as organ-specific regulators rather than hormones; they do not supply thyroxine and are not a thyroid hormone replacement.\n\nThe proposed mechanism follows the broader Khavinson short-peptide model. Unlike conventional peptide hormones, these very short, charged peptides are thought to be small enough to enter the cytoplasm and nucleus, where they bind specific nucleotide sequences in gene promoter regions, locally weaken the DNA double helix, and modulate transcription of a defined set of genes [2][4][5]. Applied to the thyroid, the peptides are claimed to be selective for thyroid follicular cells, supporting thyrocyte metabolism and self-renewal and thereby helping to normalize the gland's output of T3, T4, and calcitonin toward a physiological set point rather than forcing it in one direction [1]. In this framework the peptide acts as an epigenetic-style regulator that helps switch on tissue-appropriate gene programs, which is the rationale offered for why it is described as correcting both reduced and excessive thyroid activity. It must be stressed that this evidence is largely preclinical or from small Russian clinical series and originates mostly from a single research lineage; no independent, large-scale human pharmacology exists.\n\nPharmacokinetics have not been formally characterized for Thyreogen. As short, unmodified peptides they are expected to be rapidly hydrolyzed by gastrointestinal, plasma, and tissue peptidases, giving a free-peptide half-life on the order of minutes; any sustained effect is attributed to downstream changes in gene expression rather than continued presence of the intact peptides. Oral bioavailability of such peptides is low because of digestive proteolysis, which is why the marketed capsules deliver a relatively large 10 mg peptide load and why a sublingual ("lingual") version is also sold to favor mucosal absorption.\n\nClinically and historically the thyroid bioregulator has been delivered as oral capsules (Thyreogen, about 10-40 mg of peptide complex per day before meals in one-month courses) or, in cytomedin form, by intramuscular injection in short seasonal courses [1][3]. The once-daily subcutaneous reconstitution described on this page is an educational modeling convention, not a route validated for Thyreogen. Reconstituting a 20 mg vial in 2 mL of bacteriostatic water gives 10 mg/mL, so a 1-2 mg dose corresponds to 10-20 units on a U-100 syringe. Thyreogen remains an unapproved supplement-grade compound, and the dosing here should be read as reference information only, not therapeutic guidance.
Clinical Trial Efficacy Highlights
- starIn a clinical study of elderly residents of the Magadan Region (an iodine-poor, climatically extreme area), Gorbachev, Khavinson, and colleagues reported that the injectable thyroid cytomedin Thyramin, the pharmaceutical counterpart of Thyreogen, provided adequate correction of both subclinical and symptomatic age-related hypothyroidism; this is the most directly thyroid-specific clinical signal for the bioregulator class [1].
- starA clinical report on complex treatment of autoimmune thyroiditis applied a combined low-molecular-weight peptide complex from thyroid and pineal glands (the same cytomedin family as Thyreogen) and described improved general health and laboratory indicators, reduced thyroid autoantibody levels, and positive structural changes on thyroid ultrasonography, while noting it was an adjunct rather than a standalone therapy [3].
- starA 2021 systematic review in Molecules summarizing the Khavinson short-peptide program describes how 2-7 residue peptides penetrate cell nuclei and regulate tissue-specific gene expression and protein synthesis; it provides the mechanistic rationale for thyroid cytomaxes such as Thyreogen but reports no large human efficacy data [2].
- starFedoreyeva and colleagues (2011) showed with fluorescence-labeled Khavinson peptides that such short peptides penetrate the cytoplasm, nucleus, and nucleolus of HeLa cells and bind specific DNA oligonucleotide sequences in vitro, lending experimental plausibility to the nuclear DNA-binding mechanism proposed for Thyreogen [4].
- starKhavinson, Shataeva, and Chernova (2005) reported that regulatory peptides bind the DNA double helix in a manner analogous to transcription factors, supporting the gene-regulation model invoked for tissue-specific bioregulators including thyroid peptides [5].
- starKhavinson's overarching "Peptides and Ageing" review lays out the tissue-specific geroprotector framework under which Thyreogen was designed, but it presents the thyroid preparation as a preclinical and small-series concept rather than a clinically validated therapy [6].
- starAt the class level, a 15-year randomized follow-up by Korkushko, Khavinson, and colleagues found that a related Khavinson peptide bioregulator slowed aging and lowered mortality in elderly patients; this is among the strongest long-term clinical signals for the peptide family, but it studied a different (pineal/pituitary) peptide and cannot be extrapolated to Thyreogen [7].
- starA 2019 review in Clinical Epigenetics independently catalogued Khavinson di- to tetrapeptides as endogenous epigenetic modulators that can act as DNA-methylation inhibitors, situating the thyroid cytomax concept within a broader, externally authored peptide-epigenetics literature [8].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningNo controlled human safety data exist for Thyreogen specifically; its adverse-effect profile is essentially uncharacterized, and the points below are extrapolated from the Khavinson bioregulator class and from injectable peptides generally.
- warningBecause the product targets thyroid tissue, there is a theoretical risk of shifting thyroid hormone balance; people with hypothyroidism, hyperthyroidism, Graves disease, thyroid nodules, or thyroid cancer, and anyone taking levothyroxine or antithyroid drugs, should not self-treat and should have TSH and thyroid hormones monitored by a clinician.
- warningThyreogen is a bovine-tissue extract, so there is a theoretical risk of allergic or immune reactions to animal proteins and, as with all bovine-derived products, a remote transmissible-spongiform (BSE-class) concern depending on sourcing and processing controls.
- warningIn the educational subcutaneous model, injection can cause local reactions including redness, itching, swelling, bruising, or transient pain at the injection site; any injected peptide also carries a theoretical risk of hypersensitivity, so stop use and seek care for rash, hives, facial or throat swelling, or difficulty breathing.
- warningResearch- and supplement-grade peptide extracts are not manufactured to pharmaceutical drug standards, so contamination, endotoxin, inconsistent peptide content, or mislabeling are realistic risks; sterility and purity cannot be assumed.
- warningThere are no formal drug-interaction studies; combining Thyreogen with iodine supplements, thyroid medications, or other drugs should not be assumed to be inert or compatible.
- warningThyreogen has not been evaluated in pregnancy, breastfeeding, in children, or in people with active thyroid disease, and should be avoided in these groups.
- warningRegulatory status: Thyreogen is not approved by the FDA, EMA, or any major regulator as a drug. In Russia it is registered as a dietary supplement (biologically active additive), and elsewhere it is sold for research or educational use only. It should not be confused with Thyrogen (thyrotropin alfa), an unrelated, FDA-approved recombinant TSH used in thyroid cancer management.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Thyreogen dosage?expand_more
The most commonly cited Thyreogen dosage is the oral capsule regimen: 1-2 capsules (each containing 10 mg of peptide complex A-2) taken once or twice a day, 15-20 minutes before meals, for a one-month course, repeated two to three times per year. That corresponds to roughly 10-40 mg of peptide complex per day by mouth. The educational subcutaneous reference modeled on this page uses about 1-2 mg per day reconstituted from a 20 mg vial. Treat all of these as illustrative reference figures, not therapeutic recommendations, because no large controlled trials have established a safe or effective Thyreogen dose in humans.
Is Thyreogen FDA approved?expand_more
No. Thyreogen is not approved by the FDA, the EMA, or any other major regulator as a drug, and there are no large published randomized human trials. In Russia it is registered as a dietary supplement (a biologically active additive) within Vladimir Khavinson's peptide bioregulator program, and elsewhere it is sold for research or educational use only. Note that Thyreogen should not be confused with Thyrogen (thyrotropin alfa), which is a different, FDA-approved recombinant human TSH used in thyroid cancer testing and treatment. Nothing on this page should be read as a claim that Thyreogen is safe or effective for treating any condition.
How do you reconstitute Thyreogen?expand_more
The real Thyreogen product is an oral capsule and requires no reconstitution. For the educational injectable model shown here, you would draw 2 mL of bacteriostatic water and inject it slowly down the inner wall of a 20 mg vial, then swirl gently (never shake) until the powder dissolves into a clear solution. This gives a concentration of 10 mg/mL, so 1 mg is 10 units (0.1 mL) and 2 mg is 20 units (0.2 mL) on a U-100 insulin syringe. Swab the stopper before each draw, keep the vial refrigerated at 2-8 °C, and discard it after about 3-4 weeks. This Thyreogen reconstitution math is a reference modeling convention only, not the product's actual route.
What is Thyreogen's half-life?expand_more
Thyreogen's half-life has not been formally characterized in published pharmacokinetic studies. As a complex of short, unmodified peptide fractions, the intact molecules are expected to be broken down rapidly by digestive, plasma, and tissue peptidases, giving a free-peptide half-life on the order of minutes. The Khavinson framework attributes any longer-lasting effect to downstream changes in gene expression that outlast the peptides themselves, rather than to sustained circulating drug levels, which is part of why these bioregulators are dosed in short one-month courses a few times a year rather than continuously.
Can Thyreogen be stacked with other Khavinson bioregulators?expand_more
In the bioregulator literature, tissue-specific cytomaxes are frequently described as being combined; the autoimmune thyroiditis study that supports this class actually used a thyroid peptide alongside a pineal peptide, and Thyreogen is commonly marketed next to pineal (Endoluten/Epitalon), thymic (Vladonix), and other organ peptides. However, there are no controlled data on the safety, interactions, or added benefit of any such stack, and combining unapproved supplement- or research-grade peptides multiplies the unknown risks, especially when the thyroid is involved. This is general information, not medical advice; anyone considering these compounds should consult a qualified clinician and have thyroid function monitored.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Thyreogen, plus the universal dosing calculator.
Academic References & Study Citations
Gorbachev AL, Lugovaia EA, Ryzhak GA, Khavinson VKh. [Peptide bioregulator efficacy in the correction of reduced thyroid gland function in the residents of Magadan Region]. Adv Gerontol. 2005;16:80-87. Russian. View Scientific Paper →
Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. View Scientific Paper →
Gorgiladze D, Pinaev R, Aleksandrov V. Application of Peptides for Complex Treatment of Autoimmune Thyroiditis. Innovation in Aging. 2017;1(Suppl 1) (GSA Annual Scientific Meeting abstract). View Scientific Paper →
Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-1219. View Scientific Paper →
Khavinson VKh, Shataeva LK, Chernova AA. DNA double-helix binds regulatory peptides similarly to transcription factors. Neuro Endocrinol Lett. 2005;26(3):237-241. View Scientific Paper →
Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. View Scientific Paper →
Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366-369. View Scientific Paper →
Janssens Y, Wynendaele E, Vanden Berghe W, De Spiegeleer B. Peptides as epigenetic modulators: therapeutic implications. Clin Epigenetics. 2019;11(1):101. View Scientific Paper →